Status:
UNKNOWN
14-day Double Therapy Versus Bismuth Quadruple Therapy in First-line Treatment of Helicobacter Pylori Infection
Lead Sponsor:
Shandong University
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The researchers collected untreated H. pylori positive patients from outpatient clinics. Subjects were randomized to 14 days of dual therapy with Tegoprazan or 14 days of quadruple therapy with bismut...
Detailed Description
1. Informed consent: Patients with positive Helicobacter pylori were collected in the outpatient department, and the subjects receiving initial treatment signed informed consent. 2. Safety evaluation:...
Eligibility Criteria
Inclusion
- Helicobacter pylori infection (either positive for Helicobacter pylori culture, histopathological test, rapid urease test, C13/C14 urea breath test, or helicobacter pylori antigen test in feces).
- Patients who have not previously received helicobacter pylori eradication therapy.
Exclusion
- Serious underlying diseases, such as liver insufficiency, renal insufficiency, immunosuppression, malignant tumor, coronary heart disease (angina pectoris or coronary artery stenosis ≥ 75%).
- Those who are not willing to take contraceptive measures during pregnancy, lactation or the trial.
- Active gastrointestinal bleeding.
- History of drug allergy.
- Medication history of bismuth, antibiotics and PPI within 4 weeks.
- Other behaviors that may increase the risk, such as alcohol and drug abuse.
- Unable or unwilling to provide informed consent.
Key Trial Info
Start Date :
February 14 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
258 Patients enrolled
Trial Details
Trial ID
NCT05438550
Start Date
February 14 2023
End Date
December 31 2023
Last Update
February 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu hosipital
Jinan, Shandong, China, 250012